VANCOUVER, Nov. 20, 2014 /PRNewswire/ - Norsat International Inc. ("Norsat" or "the Company") (TSX: NII and OTC BB: NSATF), a leading provider of innovative communication solutions that enable the transmission of data, audio and video for remote and challenging applications, today announced that its management team will deliver its investor presentation at the LD Micro Conference at the Luxe Hotel in Los Angeles, CA. Dr. Amiee Chan, president and chief executive officer of Norsat and Mr. Arthur Chin, chief financial officer will be making their presentation on Wednesday, December 3, 2014 at 10:00am PT in Track Four.

Dr. Amiee Chan commented, "We are pleased to be attending this year's LD Micro Conference and excited to share the Norsat story. Over the past few years we have successfully created a line of products to effectively address the remote and challenging communications market, while operating the business in an efficient manner with a focus on cash flows. With our renewed focus on investor outreach, particularly in the United States, it is an exciting time to learn about Norsat and we are looking forward to meeting new investors at the LD Micro Conference."

About Norsat International Inc.

Founded in 1977, Norsat International Inc. is a leading provider of innovative communication solutions that enable the transmission of data, audio and video for remote and challenging applications. Norsat's products and services include leading-edge product design and development, production, distribution and infield support and service of fly-away satellite terminals, microwave components, antennas, Radio Frequency (RF) conditioning products, maritime based satellite terminals and remote network connectivity solutions. More information is available at www.norsat.com, via email at investor@norsat.com or by phone at 1-604-821-2800.

Forward Looking

The discussion and analysis of this news release contains forward-looking statements concerning anticipated developments in Norsat's operations in future periods, the adequacy of its financial resources and other events or conditions that may occur in the future. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates,", "predicts," "potential," "targeted," "plans," "possible" and similar expressions, or statements that events, conditions or results "will," "may," "could" or "should" occur or be achieved. These forward-looking statements include, without limitation, statements about Norsat's market opportunities, strategies, competition, expected activities and expenditures as it pursues its business plan, the adequacy of available cash resources and other statements about future events or results. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, such as business and economic risks and uncertainties. The forward-looking statements are based on the beliefs, expectations and opinions of management on the date the statements are made. Consequently, all forward-looking statements made in this news release are qualified by this cautionary statement and there can be no assurance that actual results or anticipated developments will be realized. For the reasons set forth above, investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this news release and Norsat assumes no obligation to update or revise them to reflect new events or circumstances, other than as required by law.

SOURCE Norsat International Inc.

Copyright 2014 PR Newswire

Grafico Azioni THC Farmaceuticals (PK) (USOTC:CBDG)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di THC Farmaceuticals (PK)
Grafico Azioni THC Farmaceuticals (PK) (USOTC:CBDG)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di THC Farmaceuticals (PK)